Addressing Immunological Factors in Managing Thin Endometrium: A Clinical Approach to Enhance Fertility Outcomes

Abstract

Thin endometrium, defined as an endometrial lining less than 7 mm in thickness, presents a significant barrier to successful pregnancy in women undergoing assisted reproductive technologies (ART)[1]. Immune system dysregulation, including autoimmune diseases and chronic inflammation, plays a critical role in reducing endometrial receptivity, making implantation difficult. This article explores the immunological aspects of thin endometrium, reviewing how immune factors, such as cytokines, autoantibodies, and altered immune cell function, contribute to poor implantation outcomes[2]. Furthermore, it proposes a clinical approach that integrates immunomodulatory therapies, including corticosteroids, intravenous immunoglobulin (IVIG), and mesenchymal stem cell therapy, to improve endometrial receptivity and ART success in women affected by immune-related endometrial dysfunction[3].